NEXL Message Board - Msg: 12824721

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEXL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Stock Puppy who wrote (1600)	2/9/2000 5:39:00 PM
From: Superhawk	of 1704

Stock Puppy: You wrote that the thread's been quiet lately. You said, "Let's talk". I bought into Nexell (plus several other biotechs) early last week. Nexell scored at the top of my rather long list of "junior" biotech plays. (BTW, I started the Curagen (CRGN) thread and provided the first two posts some time ago -- note the price action in that stock since its IPO). NEXL's low share price provides plenty of room for price appreciation -- a ten-bagger or more is possible. Its business niche of cell-separation technology/cancer therapeutics has great growth potential and investor visibility. NEXL has an international sales presence. Nine-month revenues rose slightly (2%) to $9.3M -- not bad. Their float is a tractable 47.3M shares. Market cap is an appealing $186M. They have $23.5M in cash and 43 cents a share book value. The only downside on the balance sheet (and it's a big one in my view) is a terrible debt-to-equity ratio of 1.8. This leverage will exert a significant drag on the company unless it's retired in a timely way. OK for a start to the discussion?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next